证券代码：600713 证券简称：南京医药 编号：ls2025-101 债券代码：110098 债券简称：南药转债 1 附件： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 8 月 7-8 日，南京医药股份有限公司（以下简称"公司"）第十届董 事会第二次会议审议通过《关于聘任公司部分高级管理人员的议案》，现将具体 情况公告如下： 经总裁提名，董事会提名与人力资源规划委员会审核资格通过，公司第十届 董事会第二次会议同意聘任肖宏先生、彭玉萍女士、倪华安先生、蔡鸣宇先生为 公司副总裁并作为职业经理人进行管理，任期与公司第十届董事会任期一致。 公司董事会提名与人力资源规划委员会对聘任的高级管理人员任职资格进 行了事前审核后认为，公司拟聘任的高级管理人员符合《公司法》和《公司章程》 等规定的任职资格条件，目前没有《公司法》规定的不适合担任上市公司高级管 理人员的情形。其教育背景、工作经历和身体状况能够胜任所聘岗位的职责要求， 有利于公司的健康可持续发展。 特此公告 南京医药股份有限公司董事会 2025 年 8 月 9 日 ...

| 证券简称：南京医药 编号：ls2025-102 | | --- | | 证券代码：600713 | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）子公 司福建同春药业股份有限公司（以下简称"福建同春"）本次使用部分暂时闲置 募集资金 1.5 亿元分别购买招商银行点金系列看涨两层区间 94 天结构性存款、 招商银行智汇系列看跌两层区间 21 天结构性存款。 特别风险提示：尽管公司购买的结构性存款安全性较高、流动性较好、 风险较低，但金融市场受宏观经济的影响较大，公司将根据经济形势以及金融市 场的变化合理地进行投资，但不排除该项投资受到市场波动风险、利率风险、流 动性风险、政策风险、信息传递风险、不可抗力风险等风险的影响。 一、前次使用部分暂时闲置募集资金进行现金管理到期赎回情况 2025 年 2 月 ...

| | | 南京医药股份有限公司 第十届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 债券代码：110098 债券简称：南药转债 （2）同意聘任彭玉萍女士为公司副总裁并作为职业经理人进行管理，任期 与公司第十届董事会任期一致； 同意 9 票、反对 0 票、弃权 0 票 （3）同意聘任倪华安先生为公司副总裁并作为职业经理人进行管理，任期 与公司第十届董事会任期一致。 同意 9 票、反对 0 票、弃权 0 票 （4）同意聘任蔡鸣宇先生为公司副总裁并作为职业经理人进行管理，任期 与公司第十届董事会任期一致。 同意 9 票、反对 0 票、弃权 0 票 南京医药股份有限公司第十届董事会第二次会议于 2025 年 8 月 7-8 日以通 讯方式召开，会议召开符合《公司法》和《公司章程》的规定。会议应参会董事 9 人，实际参会董事 9 人，董事周建军先生、张靓先生、徐健男女士、陆志虹先 生、骆训杰先生、Marco Kerschen 先生，独立董事王春晖先生、陆银娣女士、吕 ...

Group 1: Industry Overview - The Chinese pharmaceutical distribution market can be divided into three competitive tiers, with the first tier consisting of national wholesale giants such as China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong, all generating over 100 billion in revenue [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoyao Pharmacy and Yifeng Pharmacy, indicating significant changes in the top five rankings compared to the previous year [3] - The e-commerce segment is led by Ark Health's online pharmacy, which is pioneering a new H2H (Hospital To Home) smart healthcare model [4] Group 2: Strategic Analysis - The strategic cluster analysis of listed companies in the pharmaceutical distribution industry indicates that leaders such as China Resources Pharmaceutical, Shanghai Pharmaceuticals, Jiuzhoutong, and China National Pharmaceutical Group have revenues exceeding 100 billion and are well-established in the market [5] - The competitive landscape is characterized by intense competition, with numerous participants including wholesale and retail pharmaceutical companies, as well as brand operators entering the supply chain [7] Group 3: Competitive Forces - The analysis using Porter's Five Forces model reveals a highly competitive environment in the pharmaceutical distribution industry, with a quantification of competitive forces ranging from 0 (minimum) to 1 (maximum) [7]

Core Insights - The Chinese pharmaceutical distribution market is segmented into three competitive tiers, with major players like China National Pharmaceutical, Shanghai Pharmaceuticals, and China Resources Pharmaceutical leading the first tier with revenues exceeding 100 billion [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoda Pharmacy and Yifeng Pharmacy, indicating significant changes in the rankings from 2022-2023 [3][4] - In the e-commerce sector, Fangzhou Jianke leads the online pharmacy rankings, emphasizing the shift towards technology-driven healthcare solutions [5] Competitive Landscape - The pharmaceutical distribution industry is characterized by intense competition, with numerous participants including wholesale, retail, and brand operation companies, as well as e-commerce platforms entering the market [7] - The five forces analysis indicates a high threat from potential entrants and moderate bargaining power from downstream medical institutions and patients [7] - The strategic cluster analysis reveals that leading companies like China Resources Pharmaceutical and Shanghai Pharmaceuticals are positioned as market leaders due to their extensive experience and comprehensive business layouts [5][6] Retail Pharmacy Rankings - The top five retail pharmacies are Dazhenlin, Guoda Pharmacy, Yifeng Pharmacy, Laobaiyi, and Yixintang, reflecting a dynamic market with significant shifts in rankings [3][4] - Other notable pharmacies in the top 25 include Henan Zhang Zhongjing Pharmacy and Shandong Yanjitang, showcasing a diverse competitive landscape [3] E-commerce Pharmacy Rankings - Fangzhou Jianke leads the online pharmacy sector, followed by 1Yao.com and JD Health, highlighting the growing importance of digital platforms in the pharmaceutical distribution market [5] - The focus on technology and innovation is evident as companies aim to connect patients with medical services more effectively [5]

Group 1 - The core point of the article is that Nanjing Pharmaceutical has repurchased approximately 16.30 million shares, accounting for 1.25% of the total share capital as of July 31, 2025 [2] - The company's revenue composition for the year 2024 is as follows: wholesale accounts for 94.72%, retail for 4.53%, e-commerce for 0.48%, other businesses for 0.24%, and third-party logistics for 0.03% [2]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has announced the use of temporarily idle raised funds for cash management and the progress of its share repurchase plan, indicating a strategic approach to optimize financial resources and enhance shareholder value [1][3]. Group 1: Cash Management - The company and its subsidiaries have been authorized to use up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1]. - On July 3, 2025, the subsidiary Fujian Tongchun Pharmaceutical Co., Ltd. invested 40 million yuan in a structured deposit product from China Merchants Bank, which matured on July 31, 2025, yielding a return of 46,000 yuan [2]. - The principal and earnings from the structured deposit have been returned to the dedicated raised funds account, aligning with the company's cash management strategy [2]. Group 2: Share Repurchase - On March 14, 2025, the company approved a share repurchase plan with a total funding range of 70 million to 131.58 million yuan, with a maximum repurchase price of 7.31 yuan per share, to support the 2025 restricted stock incentive plan [3]. - As of July 31, 2025, the company has repurchased a total of approximately 16.30 million shares, representing 1.25% of the total share capital, with a total expenditure of approximately 80.26 million yuan [4]. - The repurchase activities are in compliance with relevant regulations and the company's established repurchase plan, with ongoing disclosures to keep investors informed [5].

Group 1 - The company announced a share repurchase plan with a total expected amount between 70 million and 131.58 million RMB, with a repurchase price not exceeding 7.31 RMB per share [1] - The repurchase period is set from March 14, 2025, to March 14, 2026, and the shares will be used for the 2025 restricted stock incentive plan [1] - As of July 31, 2025, the company has repurchased a total of 16.299951 million shares, accounting for 1.25% of the total share capital, with a total expenditure of 80.2576 million RMB [2] Group 2 - The highest repurchase price recorded was 5.22 RMB per share, while the lowest was 4.69 RMB per share [2] - The total share capital increased from 1,308,916,414 shares at the end of June 2025 to 1,308,927,729 shares at the end of July 2025 due to the conversion of the company's convertible bonds [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [2]

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1] Group 1: Cash Management Approval - The board of directors and the supervisory board approved the cash management proposal during meetings held from January 20 to 22, 2025 [1] - The cash management usage period is valid for 12 months from the date of board approval, with the option for rolling use [1] Group 2: Redemption and Returns - Fujian Tongchun used 40 million yuan of temporarily idle funds to purchase a structured deposit from China Merchants Bank, which matured on July 31, 2025, yielding a return of 46,000 yuan [2] - The principal and returns from the structured deposit have been returned to the dedicated fundraising account [2] Group 3: Recent Cash Management Activities - In the last 12 months, the company has invested a total of 202.9 million yuan in various cash management products, with a total return of 227,490 yuan [3] - The highest single-day investment in the last 12 months was 70 million yuan, representing 10.24% of the audited net assets for the past year [3] Group 4: Current Cash Management Status - The total cash management limit is 70 million yuan, with 46.2 million yuan already utilized and 23.8 million yuan remaining available for use [4]

Core Viewpoint - Nanjing Pharmaceutical announced the completion of a share buyback program, having repurchased a total of 16,299,951 shares as of July 31, 2025 [2] Summary by Relevant Sections - **Company Actions** - The company has executed a share buyback through centralized bidding, accumulating a total of 16,299,951 shares [2] - **Timeline** - The share buyback program is set to conclude on July 31, 2025 [2]